JNJ - Johnson & Johnson
| Previous close | 141.34 |
| Open | 141.10 |
| Bid | 141.39 x 1000 |
| Ask | 141.51 x 1100 |
| Day's range | 140.31 - 141.80 |
| 52-week range | 121.00 - 144.98 |
| Volume | 3824826 |
| Avg. volume | 7,199,685 |
| Market cap | 372B |
| Beta (5Y Monthly) | 0.70 |
| PE ratio (TTM) | 26.97 |
| EPS (TTM) | 5.24 |
| Earnings date | 22 Jan 2020 |
| Forward dividend & yield | 3.80 (2.69%) |
| Ex-dividend date | 2019-11-25 |
| 1y target est | 150.78 |
- Zacks
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
Johnson & Johnson (JNJ) closed at $139.99 in the latest trading session, marking a -0.36% move from the prior day.
- Zacks
J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH
J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.
- Zacks
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar
FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.
- Zacks
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
- Zacks
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
- Zacks
J&J Stock Witnesses Volatility in '19: What to Expect in 2020
Here we discuss the ups and downs of J&J's (JNJ) stock this year.
- Zacks
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $139.38, moving +1.62% from the previous trading session.
- Zacks
AstraZeneca Sells Schizophrenia Drug Rights in US and Canada
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
- Zacks
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
- Reuters
J&J says new tests show no asbestos in Johnson's Baby Powder
A total of 155 tests were conducted by two different third-party labs using four different testing methods on samples from the same bottle tested by the FDA's contracted lab, the company said. The tests are the latest effort by J&J to prove the safety of its widely used consumer product after the test by the FDA prompted J&J to undertake a nationwide recall of one lot of Johnson's Baby Powder in October.
- Reuters
Special Report - Powder Keg: FDA bowed to industry for decades as alarms were sounded over talc
The “Asbestos in Talc Symposium,” sponsored by the Food and Drug Administration, was dominated by industry hands: Most of the 21 non-government participants had done work for talc companies, such as testing and serving as expert witnesses and consultants, symposium documents and other records show. Key sessions were led by witnesses for Johnson & Johnson in lawsuits alleging the company failed to warn customers that its Baby Powder was tainted with cancer-causing asbestos, the records show. Over the past 50 years, the FDA has relied upon - and often deferred to - industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
- Yahoo Finance
The uniquely American opioid crisis, in 3 charts
And according to data from Deutsche Bank Research, opioid-related deaths per million inhabitants has drastically increased in the U.S. compared to the other Organization for Economic Cooperation and Development (OECD) countries.
- Zacks
Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
- Zacks
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
Style Box ETF report for IWX
- Zacks
Fed Reportedly Opens Criminal Investigation on Opioid Makers
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
- Yahoo Finance
Stock Market Live Updates: Markets close at record highs
Headlines moving the stock market in real time.
- Yahoo Finance
Why mental health coverage is still a struggle for employer-sponsored plans
New report sets stage for greater mental health coverage.
- Reuters - UK Focus
AstraZeneca shares rise on early U.S. approval for leukaemia drug
AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie. AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company's Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukaemia in adults. The drug was approved under a new speedy review programme in collaboration with drug watchdogs in Canada and Australia, and was also approved to treat small lymphocytic lymphoma, a similar disease.
- Investing.com
NewsBreak: Trump Looks to Let Florida, Others Import Prescription Drugs
Investing.com – President Donald Trump tweeted on Friday the federal government is working on a plan to let Florida and other states import lower-priced prescription drugs for residents.
- Reuters - UK Focus
Sanofi weighing options for consumer healthcare unit-sources
FRANKFURT/PARIS, Nov 21 (Reuters) - Sanofi is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month. An initial public offering (IPO) of the unit, which could be worth around $30 billion according to two sources familiar with the matter, is also on the cards. Sources cautioned that no final decision had been made.
- Reuters
Johnson & Johnson loses pelvic mesh class action in Australia
More than 1,350 Australian women won a seven-year-old class action lawsuit on Thursday against Johnson & Johnson (J&J) for misleading patients and surgeons about the risks of the pharmaceutical giant's pelvic mesh implants. The suit is one of many J&J has faced in the United States, Canada and Europe over the implants, used to treat urinary incontinence and pelvic organ prolapse, in which organs shift from normal positions. J&J in October agreed to pay nearly $117 million to resolve claims in 41 U.S. states and the District of Columbia.
- Zacks
Myovant Up on Successful Completion of Prostate Cancer Study
Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.
